SEARCH:   Advanced

Blood, 15 January 2005, Vol. 105, No. 2, pp. 545-547. Prepublished online as a Blood First Edition Paper on September 28, 2004; DOI 10.1182/blood-2004-01-0322. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-01-0322v1 105/2/545    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bakanay, S. M. Articles by Kutlar, A. Search for Related Content PubMed PubMed Citation Articles by Bakanay, S. M. Articles by Kutlar, A. Related Collections Brief Reports Clinical Trials and Observations Red Cells Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Brief report Mortality in sickle cell patients on hydroxyurea therapy Sule M. Bakanay, Erin Dainer, Betsy Clair, Adekunle Adekile, Lisa Daitch, Leigh Wells, Leslie Holley, David Smith, and Abdullah Kutlar From the Sickle Cell Center, Department of Medicine, Office of Biostatistics and Bioinformatics, Medical College of Georgia, Augusta. The efficacy of hydroxyurea (HU) and its role in the reduction in mortality in sickle cell patients has been established. Nevertheless, many patients still die of complications of this disease while on HU. Of the 226 patients treated with HU at our center, 38 died (34 of sickle cell–related causes). Acute chest syndrome (ACS) was the most common (35%) cause of death. Deceased and surviving patients did not differ significantly in average HU dose, baseline fetal hemoglobin (Hb F), or maximum Hb F response. However, the deceased patients were significantly older when HU was instituted, were more anemic, and more likely to have BAN or CAM haplotypes. They also had significantly higher serum blood-urea-nitrogen (BUN) and creatinine levels. Sickle cell patients who die while on HU therapy may represent a subgroup of older patients, possibly with more severe disease and more severe organ damage. Such patients need early identification and prompt HU institution. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Sickle cell disease and hydroxyurea: the good, the bad, and the future Martin H. Steinberg Blood 2005 105: 441. [Full Text] [PDF] This article has been cited by other articles: I. Berthaut, G. Guignedoux, F. Kirsch-Noir, V. de Larouziere, C. Ravel, D. Bachir, F. Galacteros, P.-Y. Ancel, J.-M. Kunstmann, L. Levy, et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males Haematologica, July 1, 2008; 93(7): 988 - 993. [Abstract] [Full Text] [PDF] B. C. McClain and Z. N. Kain Pediatric Palliative Care: A Novel Approach to Children With Sickle Cell Disease Pediatrics, March 1, 2007; 119(3): 612 - 614. [Full Text] [PDF] G. R. Buchanan and M. J. Kahn Hemolytic anemias ASH Self-Assessment Program, January 1, 2007; 2007(1): 102 - 142. [Full Text] [PDF] A. D. Villella Mortality in Sickle Cell Patients on Hydroxyurea Therapy AAP Grand Rounds, August 1, 2005; 14(2): 14 - 15. [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020